Prognostic and safety analysis of capecitabine monotherapy versus CapeOx (capecitabine plus oxaliplatin) in elderly patients with high-risk stage II and stage III MRD-negative colorectal cancer
Capecitabine monotherapy might provide comparable DFS to CapeOx in elderly MRD-negative CRC patients, with better safety profile. MRD status might guide personalized dose-reduction strategies for elderly patients with high-risk stage II and stage III CRC.
Authors
- Xianjin Huang
- Zhenhao Quan
- Wen‐Ting Ou (ORCID: https://orcid.org/0000-0003-3090-8522)
- Jiawei Zhai
- Lijun Sun (ORCID: https://orcid.org/0000-0002-5954-6679)
- Jiayuan Wu (ORCID: https://orcid.org/0000-0002-4626-2773)
- Caijin Zhou (ORCID: https://orcid.org/0000-0003-0951-9127)
- Rongjian Tan
Institutions
- Guangdong Medical College (CN)
- Affiliated Hospital of Guangdong Medical College Hospital (CN)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/jgo-2025-504
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00